Detalles de la búsqueda
1.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Diabetes Obes Metab
; 26(3): 961-970, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38073422
2.
Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes.
Endocr J
; 71(4): 403-408, 2024 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38403638
3.
Positive association between proinsulin and fatty liver index in people with type 2 diabetes.
Endocr J
; 71(2): 193-197, 2024 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38123335
4.
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
Endocr J
; 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38658349
5.
Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study.
Diabetes Obes Metab
; 25(7): 1883-1889, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36906821
6.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Diabetes Obes Metab
; 25(6): 1503-1511, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36722623
7.
Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis.
Pituitary
; 25(2): 321-327, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35088194
8.
Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
Endocr J
; 69(5): 495-509, 2022 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34819409
9.
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.
Diabetes Obes Metab
; 21(3): 710-714, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30311367
10.
A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study).
Diabetes Obes Metab
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38699794
11.
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Cardiovasc Diabetol
; 16(1): 125, 2017 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29017497
12.
Improvement of ß-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
J Clin Endocrinol Metab
; 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38695547
13.
Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease.
Diabetes Metab J
; 48(3): 473-481, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38419467
14.
Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.
Pharmaceutics
; 15(8)2023 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37631377
15.
Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Medicine (Baltimore)
; 102(51): e36664, 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38134115
16.
Favorable Effect of Pemafibrate on Insulin Resistance and ß-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study.
Pharmaceutics
; 15(7)2023 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37514025
17.
Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage.
Diabetol Metab Syndr
; 15(1): 214, 2023 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880780
18.
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
BMJ Open Diabetes Res Care
; 10(6)2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36379585
19.
Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.
J Diabetes Res
; 2022: 5603864, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35097130
20.
The agreement between measured HbA1c and optimized target HbA1c based on the Dementia Assessment Sheet for Community-based Integrated Care System 8-items (DASC-8): A cross-sectional study of elderly patients with diabetes.
Geriatr Gerontol Int
; 22(8): 560-567, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35773969